Immune Checkpoint Inhibitor-Associated Nephritis – Treatment Standard (2024) Elena-Bianca Barbir

Description

This article reviews the developments in understanding the pathophysiology, diagnosis, prognostic factors, and current treatment standards for Immune Checkpoint Inhibitor-Associated Acute Kidney Injury (ICI-AKI). It notes that ICI-AKI, frequently presenting as acute tubulointerstitial nephritis, affects 2-5% of patients treated with ICIs. Treatment involves holding ICIs, discontinuing associated drugs, and initiating immunosuppression with corticosteroids.